Prof. Dr. Alexander Steinkasserer
Mallia Therapeutics
Prof.Dr. Alexander Steinkasserer, studied Biology at the University of Innsbruck and graduated in 1998 (PhD). Next, he was offered a postdoctoral position at the Department of Immunology at the LM-Universität München, where he worked for 3.5 years. Subsequently, he went to the University of Oxford and performed research at the Department of Biochemistry, as a postdoctoral fellow of the “Oxford Centre of Molecular Sciences”, for 4 years. Then, he worked for 5 years at the pharmaceutical industry, first at the Novartis Research Institute, as a lab head, and then at the Baxter AG, as a division head, in Vienna. In 1998 he was appointed University Professor at the Friedrich-Alexander Universität-Erlangen-Nürnberg (FAU), at the University Hospital Erlangen, heading the Department of Immune Modulation. Since then, the CD83 molecule was at the centre of his research interest, both in the field of autoimmunity and transplantation as well as in respect to virus induced immune modulations. Very interestingly, in recent years, we discovered that sCD83 also strongly improves wound healing and induces new hair growth. Noteworthy, no other treatment option is able to induce new hair growth. Finally, this discovery was also the basis for the foundation of the company Mallia-Therapeutics GmbH, together with Dr. Manfred Groeppel and Dr. Dmytro Royzman, in June 2023. The aim of the company is to develop the soluble CD83 molecule as a new therapeutic product for topical treatment of hair loss.